|
1
|
Schima W, Ba-Ssalamah A, Kölblinger C,
Kulinna-Cosentini C, Puespoek A and Götzinger P: Pancreatic
adenocarcinoma. Eur Radiol. 17:638–649. 2007.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Neoptolemos JP, Dunn JA, Stocken DD,
Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P,
Dervenis C, et al: Adjuvant chemoradiotherapy and chemotherapy in
resectable pancreatic cancer: A randomised controlled trial.
Lancet. 358:1576–1585. 2001.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Girelli R, Frigerio I, Giardino A, Regi P,
Gobbo S, Malleo G, Salvia R and Bassi C: Results of 100 pancreatic
radiofrequency ablations in the context of a multimodal strategy
for stage III ductal adenocarcinoma. Langenbecks Arch Surg.
398:63–69. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Singh SM, Longmire WP Jr and Reber HA:
Surgical palliation for pancreatic cancer. The UCLA experience. Ann
Surg. 212:132–139. 1990.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Huguet F, Girard N, Guerche CS, Hennequin
C, Mornex F and Azria D: Chemoradiotherapy in the management of
locally advanced pancreatic carcinoma: A qualitative systematic
review. J Clin Oncol. 27:2269–2277. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Paiella S, Salvia R, Ramera M, Girelli R,
Frigerio I, Giardino A, Allegrini V and Bassi C: Local ablative
strategies for ductal pancreatic cancer (radiofrequency ablation,
irreversible electroporation): A review. Gastroenterol Res Pract.
2016(4508376)2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Rocha Lima CM, Green MR, Rotche R, Miller
WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G and
Miller LL: Irinotecan plus gemcitabine results in no survival
advantage compared with gemcitabine monotherapy in patients with
locally advanced or metastatic pancreatic cancer despite increased
tumor response rate. J Clin Oncol. 22:3776–3783. 2004.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Louvet C, Labianca R, Hammel P, Lledo G,
Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, et
al: Gemcitabine in combination with oxaliplatin compared with
gemcitabine alone in locally advanced or metastatic pancreatic
cancer: Results of a GERCOR and GISCAD phase III trial. J Clin
Oncol. 23:3509–3516. 2005.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Poplin E, Feng Y, Berlin J, Rothenberg ML,
Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P,
et al: Phase III, randomized study of gemcitabine and oxaliplatin
versus gemcitabine (fixed-dose rate infusion) compared with
gemcitabine (30-min infusion) in patients with pancreatic carcinoma
E6201: A trial of the Eastern cooperative oncology group. J Clin
Oncol. 27:3778–3785. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Heinemann V, Haas M and Boeck S:
Neoadjuvant treatment of borderline resectable and non-resectable
pancreatic cancer. Ann Oncol. 24:2484–2492. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
He J, Page AJ, Weiss M, Wolfgang CL,
Herman JM and Pawlik TM: Management of borderline and locally
advanced pancreatic cancer: Where do we stand? World J
Gastroenterol. 20:2255–2266. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Vauthey JN and Dixon E: AHPBA/SSO/SSAT
consensus conference on resectable and borderline resectable
pancreatic cancer: Rationale and overview of the conference. Ann
Surg Oncol. 16:1725–1726. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Halperin DM and Varadhachary GR:
Resectable, borderline resectable, and locally advanced pancreatic
cancer: What does it matter? Curr Oncol Rep. 16(366)2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Katz MH, Crane CH and Varadhachary G:
Management of borderline resectable pancreatic cancer. Semin Radiat
Oncol. 24:105–112. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Benson AB III, D'Angelica MI, Abbott DE,
Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey
AM, et al: NCCN guidelines insights: Hepatobiliary cancers, version
1.2017. J Natl Compr Canc Netw. 15:563–573. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Katz MHG and Varadhachary GR: Borderline
resectable pancreatic cancer-at the crossroads of precision
medicine. Cancer. 125:1584–1587. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Varadhachary GR: Preoperative therapies
for resectable and borderline resectable pancreatic cancer. J
Gastrointest Oncol. 2:136–142. 2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gazelle GS, Goldberg SN, Solbiati L and
Livraghi T: Tumor ablation with radio-frequency energy. Radiology.
217:633–646. 2000.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Rovere-Querini P and Manfredi AA: Tumor
destruction and in situ delivery of antigen presenting cells
promote anti-neoplastic immune responses: Implications for the
immunotherapy of pancreatic cancer. JOP. 5:308–314. 2004.PubMed/NCBI
|
|
21
|
Siriwardena AK: Radiofrequency ablation
for locally advanced cancer of the pancreas. JOP. 7:1–4.
2006.PubMed/NCBI
|
|
22
|
Girelli R, Frigerio I, Salvia R, Barbi E,
Tinazzi Martini P and Bassi C: Feasibility and safety of
radiofrequency ablation for locally advanced pancreatic cancer. Br
J Surg. 97:220–225. 2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Dromi SA, Walsh MP, Herby S, Traughber B,
Xie J, Sharma KV, Sekhar KP, Luk A, Liewehr DJ, Dreher MR, et al:
Radiofrequency ablation induces antigen-presenting cell
infiltration and amplification of weak tumor-induced immunity.
Radiology. 251:58–66. 2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Giardino A, Girelli R, Frigerio I, Regi P,
Cantore M, Alessandra A, Lusenti A, Salvia R, Bassi C and Pederzoli
P: Triple approach strategy for patients with locally advanced
pancreatic carcinoma. HPB (Oxford). 15:623–627. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Shrestha B, Sun Y, Faisal F, Kim V, Soares
K, Blair A, Herman JM, Narang A, Dholakia AS, Rosati L, et al:
Long-term survival benefit of upfront chemotherapy in patients with
newly diagnosed borderline resectable pancreatic cancer. Cancer
Med. 6:1552–1562. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chu KF and Dupuy DE: Thermal ablation of
tumours: Biological mechanisms and advances in therapy. Nat Rev
Cancer. 14:199–208. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hansler J, Wissniowski TT, Schuppan D,
Witte A, Bernatik T, Hahn EG and Strobel D: Activation and
dramatically increased cytolytic activity of tumor specific T
lymphocytes after radio-frequency ablation in patients with
hepatocellular carcinoma and colorectal liver metastases. World J
Gastroenterol. 12:3716–3721. 2006.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Morganti AG, Massaccesi M, La Torre G,
Caravatta L, Piscopo A, Tambaro R, Sofo L, Sallustio G, Ingrosso M,
Macchia G, et al: A systematic review of resectability and survival
after concurrent chemoradiation in primarily unresectable
pancreatic cancer. Ann Surg Oncol. 17:194–205. 2010.PubMed/NCBI View Article : Google Scholar
|
|
29
|
D'Onofrio M, Barbi E, Girelli R, Tinazzi
Martini P, De Robertis R, Ciaravino V, Salvia R, Butturini G,
Frigerio I, Milazzo T, et al: Variation of tumoral marker after
radiofrequency ablation of pancreatic adenocarcinoma. J
Gastrointest Oncol. 7:213–220. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Matsui Y, Nakagawa A, Kamiyama Y, Yamamoto
K, Kubo N and Nakase Y: Selective thermocoagulation of unresectable
pancreatic cancers by using radiofrequency capacitive heating.
Pancreas. 20:14–20. 2000.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Spiliotis JD, Datsis AC, Michalopoulos NV,
Kekelos SP, Vaxevanidou A, Rogdakis AG and Christopoulou AN:
Radiofrequency ablation combined with palliative surgery may
prolong survival of patients with advanced cancer of the pancreas.
Langenbecks Arch Surg. 392:55–60. 2007.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Spiliotis JD, Datsis AC, Michalopoulos NV,
Kekelos SP, Vaxevanidou A, Rogdakis AG and Christopoulou AN: High
operative risk of cool-tip radiofrequency ablation for unresectable
pancreatic head cancer. J Surg Oncol. 96:89–90. 2007.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Frigerio I, Girelli R, Giardino A, Regi P,
Salvia R and Bassi C: Short term chemotherapy followed by
radiofrequency ablation in stage III pancreatic cancer: Results
from a single center. J Hepatobiliary Pancreat Sci. 20:574–577.
2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wu Y, Tang Z, Fang H, Gao S, Chen J, Wang
Y and Yan H: High operative risk of cool-tip radiofrequency
ablation for unresectable pancreatic head cancer. J Surg Oncol.
94:392–395. 2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Fegrachi S, Molenaar IQ, Klaessens JH,
Besselink MG, Offerhaus JA and van Hillegersberg R: Radiofrequency
ablation of the pancreas with and without intraluminal duodenal
cooling in a porcine model. J Surg Res. 184:867–872.
2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Fegrachi S, Besselink MG, van Santvoort
HC, van Hillegersberg R and Molenaar IQ: Radiofrequency ablation
for unresectable locally advanced pancreatic cancer: A systematic
review. HPB (Oxford). 16:119–123. 2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Fegrachi S, Molenaar IQ, Klaessens JH,
Besselink MG, Offerhaus JA and van Hillegersberg R: Radiofrequency
ablation of the pancreas: Two-week follow-up in a porcine model.
Eur J Surg Oncol. 40:1000–1007. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Date RS, Biggins J, Paterson I, Denton J,
McMahon RF and Siriwardena AK: Development and validation of an
experimental model for the assessment of radiofrequency ablation of
pancreatic parenchyma. Pancreas. 30:266–271. 2005.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Date RS and Siriwardena AK: Radiofrequency
ablation of the pancreas. II: Intra-operative ablation of
non-resectable pancreatic cancer. A description of technique and
initial outcome. JOP. 6:588–592. 2005.PubMed/NCBI
|
|
40
|
Hadjicostas P, Malakounides N, Varianos C,
Kitiris E, Lerni F and Symeonides P: Radiofrequency ablation in
pancreatic cancer. HPB (Oxford). 8:61–64. 2006.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Casadei R, Ricci C, Pezzilli R, Serra C,
Calculli L, Morselli-Labate AM, Santini D and Minni F: A
prospective study on radiofrequency ablation locally advanced
pancreatic cancer. Hepatobiliary Pancreat Dis Int. 9:306–311.
2010.PubMed/NCBI
|
|
42
|
Figueroa-Barojas P, Bakhru MR, Habib NA,
Ellen K, Millman J, Jamal-Kabani A, Gaidhane M and Kahaleh M:
Safety and efficacy of radiofrequency ablation in the management of
unresectable bile duct and pancreatic cancer: A novel palliation
technique. J Oncol. 2013(910897)2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Varshney S, Sewkani A, Sharma S, Kapoor S,
Naik S, Sharma A and Patel K: Radiofrequency ablation of
unresectable pancreatic carcinoma: Feasibility, efficacy and
safety. JOP. 7:74–78. 2006.PubMed/NCBI
|
|
44
|
Rombouts SJ, Vogel JA, van Santvoort HC,
van Lienden KP, van Hillegersberg R, Busch OR, Besselink MG and
Molenaar IQ: Systematic review of innovative ablative therapies for
the treatment of locally advanced pancreatic cancer. Br J Surg.
102:182–193. 2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Gemenetzis G, Groot VP, Blair AB, Laheru
DA, Zheng L, Narang AK, Fishman EK, Hruban RH, Yu J, Burkhart RA,
et al: Survival in locally advanced pancreatic cancer after
neoadjuvant therapy and surgical resection. Ann Surg. 270:340–347.
2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
He J, Blair AB, Groot VP, Javed AA,
Burkhart RA, Gemenetzis G, Hruban RH, Waters KM, Poling J, Zheng L,
et al: Is a pathological complete response following neoadjuvant
chemoradiation associated with prolonged survival in patients with
pancreatic cancer? Ann Surg. 268:1–8. 2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Alistar A, Morris BB, Desnoyer R, Klepin
HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R
Jr, Topaloglu U, et al: Safety and tolerability of the
first-in-class agent CPI-613 in combination with modified
FOLFIRINOX in patients with metastatic pancreatic cancer: A
single-centre, open-label, dose-escalation, phase 1 trial. Lancet
Oncol. 18:770–778. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Song TJ, Seo DW, Lakhtakia S, Reddy N, Oh
DW, Park DH, Lee SS, Lee SK and Kim MH: Initial experience of
EUS-guided radiofrequency ablation of unresectable pancreatic
cancer. Gastrointest Endosc. 83:440–443. 2016.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Carrafiello G, Ierardi AM, Fontana F,
Petrillo M, Floridi C, Lucchina N, Cuffari S, Dionigi G, Rotondo A
and Fugazzola C: Microwave ablation of pancreatic head cancer:
Safety and efficacy. J Vasc Interv Radiol. 24:1513–1520.
2013.PubMed/NCBI View Article : Google Scholar
|
|
50
|
D'Onofrio M, Crosara S, De Robertis R,
Butturini G, Salvia R, Paiella S, Bassi C and Mucelli RP:
Percutaneous radiofrequency ablation of unresectable locally
advanced pancreatic cancer: Preliminary results. Technol Cancer Res
Treat. 16:285–294. 2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Niu L, He L, Zhou L, Mu F, Wu B, Li H,
Yang Z, Zuo J and Xu K: Percutaneous ultrasonography and computed
tomography guided pancreatic cryoablation: Feasibility and safety
assessment. Cryobiology. 65:301–307. 2012.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ierardi AM, Biondetti P, Coppola A,
Fumarola EM, Biasina AM, Alessio Angileri S and Carrafiello G:
Percutaneous microwave thermosphere ablation of pancreatic tumours.
Gland Surg. 7:59–66. 2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Rossi S, Viera FT, Ghittoni G, Cobianchi
L, Rosa LL, Siciliani L, Bortolotto C, Veronese L, Vercelli A,
Gallotti A and Ravetta V: Radiofrequency ablation of pancreatic
neuroendocrine tumors: A pilot study of feasibility, efficacy, and
safety. Pancreas. 43:938–945. 2014.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Vogl TJ, Panahi B, Albrecht MH, Naguib
NNN, Nour-Eldin NA, Gruber-Rouh T, Thompson ZM and Basten LM:
Microwave ablation of pancreatic tumors. Minim Invasive Ther Allied
Technol. 27:33–40. 2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
D'Onofrio M, Zamboni G, Faccioli N,
Capelli P and Pozzi Mucelli R: Ultrasonography of the pancreas. 4.
Contrast-enhanced imaging. Abdom Imaging. 32:171–181.
2007.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Crinò SF, D'Onofrio M, Bernardoni L,
Frulloni L, Iannelli M, Malleo G, Paiella S, Larghi A and
Gabbrielli A: EUS-guided radiofrequency ablation (EUS-RFA) of solid
pancreatic neoplasm using an 18-gauge needle electrode:
Feasibility, safety, and technical success. J Gastrointestin Liver
Dis. 27:67–72. 2018.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Keane MG, Bramis K, Pereira SP and Fusai
GK: Systematic review of novel ablative methods in locally advanced
pancreatic cancer. World J Gastroenterol. 20:2267–2278.
2014.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Pai M, Habib N, Senturk H, Lakhtakia S,
Reddy N, Cicinnati VR, Kaba I, Beckebaum S, Drymousis P, Kahaleh M
and Brugge W: Endoscopic ultrasound guided radiofrequency ablation,
for pancreatic cystic neoplasms and neuroendocrine tumors. World J
Gastrointest Surg. 7:52–59. 2015.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Paiella S, De Pastena M, D'Onofrio M,
Crinò SF, Pan TL, De Robertis R, Elio G, Martone E, Bassi C and
Salvia R: Palliative therapy in pancreatic cancer-interventional
treatment with radiofrequency ablation/irreversible
electroporation. Transl Gastroenterol Hepatol. 3(80)2018.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Carrafiello G, Ierardi AM, Piacentino F,
Lucchina N, Dionigi G, Cuffari S and Fugazzola C: Microwave
ablation with percutaneous approach for the treatment of pancreatic
adenocarcinoma. Cardiovasc Intervent Radiol. 35:439–442.
2012.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Li J, Chen X, Yang H, Wang X, Yuan D, Zeng
Y, Wen T, Yan L and Li B: Tumour cryoablation combined with
palliative bypass surgery in the treatment of unresectable
pancreatic cancer: A retrospective study of 142 patients. Postgrad
Med J. 87:89–95. 2011.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Xiong LL, Hwang JH, Huang XB, Yao SS, He
CJ, Ge XH, Ge HY and Wang XF: Early clinical experience using high
intensity focused ultrasound for palliation of inoperable
pancreatic cancer. JOP. 10:123–129. 2009.PubMed/NCBI
|
|
63
|
Xiaoping L and Leizhen Z: Advances of high
intensity focused ultrasound (HIFU) for pancreatic cancer. Int J
Hyperthermia. 29:678–682. 2013.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Diana M, Schiraldi L, Liu YY, Memeo R,
Mutter D, Pessaux P and Marescaux J: High intensity focused
ultrasound (HIFU) applied to hepato-bilio-pancreatic and the
digestive system-current state of the art and future perspectives.
Hepatobiliary Surg Nutr. 5:329–344. 2016.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Ning Z, Xie J, Chen Q, Zhang C, Xu L, Song
L and Meng Z: HIFU is safe, effective, and feasible in pancreatic
cancer patients: A monocentric retrospective study among 523
patients. Onco Targets Ther. 12:1021–1029. 2019.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Martin RC: Irreversible electroporation of
locally advanced pancreatic head adenocarcinoma. J Gastrointest
Surg. 17:1850–1856. 2013.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Martin RC II, McFarland K, Ellis S and
Velanovich V: Irreversible electroporation in locally advanced
pancreatic cancer: Potential improved overall survival. Ann Surg
Oncol. 20 (Suppl 3):S443–S449. 2013.PubMed/NCBI View Article : Google Scholar
|
